Newsroom | 49077 results

DUBLIN--(BUSINESS WIRE)--The "Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets Training Course (Mar 18, 2026)" training has been added to ResearchAndMarkets.com's offering. The life sciences sector is heavily regulated and CTAs are some of the most important agreements for companies operating in this sector. Having appropriate CTAs in place is therefore essential for managing relationships between the diffe...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board of directors has determined to effect a one-for-16 reverse stock split of Adicet’s common stock, par value $0.0001 per share. The reverse stock split ratio approved by the board of directors is within the previously disclosed range of ratios for a revers...

DUBLIN--(BUSINESS WIRE)--The "Clinical Trial Supply & Logistics Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The clinical trial supply & logistics market is seeing transformative shifts driven by regulatory complexity, operational advances, and increased demand for patient-centric models. Senior leaders face evolving pressures that demand robust strategies to manage sourcing, distribution, compliance, and innovation. Market Snapshot: Cl...

UPPER NYACK, N.Y.--(BUSINESS WIRE)--GHLF English and Spanish Language Lupus Help Centers Reach New Patients...

UPPER NYACK, N.Y.--(BUSINESS WIRE)--La Fundación Global para una Vida Saludable anunció hoy un hito de éxito para su Centro de Recursos sobre Lupus en Español, un programa hermano de su ampliamente utilizado Centro de Ayuda sobre Lupus en inglés. La plataforma está diseñada para ofrecer educación culturalmente relevante, información confiable y acceso a recursos sobre ensayos clínicos para comunidades hispanohablantes en los Estados Unidos. El sitio web refuerza el compromiso de GHLF de reducir...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement. YARTEMLEA is the first and only approved lectin pathway inhibitor. YARTEMLEA selectively inhibits MASP-2, the ef...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced the appointment of Jeffrey R. Williams as Independent Director. “We are pleased to welcome Jeffrey to our Board of Directors for PharmaEssentia USA,” said Ko-Chung Lin, Ph.D., Founder and Chief Execu...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare’s polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the “Gilead Agreement”). “We are pleased to announce this transaction which combines Gilead’s leading expertise in oncology research and development with RP-3467, a potential best-in-class...

SAN DIEGO--(BUSINESS WIRE)--Janux provided a program update on its Phase 1 study of JANX008, an EGFR-targeted TRACTr, following Phase 1a completion and cohort expansion....

ROCHESTER, Minn.--(BUSINESS WIRE)--Vyriad announced $25M final tranche of its Series B to support the first-in-human testing of VV169, Vyriad’s in vivo CAR-T candidate....